Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients by Galati, D. et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/authorsrights
Author's personal copy
Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis
in idiopathic pulmonary ﬁbrosis patientsq
Domenico Galati a, Marina De Martino b, Annamaria Trotta c, Gaetano Rea d, Dario Bruzzese e,
Gaetano Cicchitto f, Anna Agnese Stanziola b, Maria Napolitano c, Alessandro Sanduzzi b,
Marialuisa Bocchino b,⇑
aDipartimento di Ematologia, IRCCS INT Fondazione Pascale, Napoli, Italy
bDipartimento di Medicina Clinica e Chirurgia, Università Federico II, Napoli, Italy
cUOSC Immunologia Oncologica, IRCCS INT Fondazione Pascale, Napoli, Italy
dDipartimento dei Servizi Diagnostici e Generali, Ospedali dei Colli, Monaldi-Cotugno-CTO, Napoli, Italy
eDipartimento di Sanità Pubblica, Università Federico II, Napoli, Italy
f Fisiopatologia Respiratoria, ASL, Salerno, Italy
a r t i c l e i n f o
Article history:
Received 5 June 2013
Received in revised form 31 October 2013
Accepted 5 December 2013
Available online 10 January 2014
Keywords:
IPF
Flow cytometry
Th17 cells
Regulatory T cells
NK cells
a b s t r a c t
The immune response plays an unsettled role in the pathogenesis of idiopathic pulmonary ﬁbrosis (IPF),
the contribution of inﬂammation being controversial as well. Emerging novel T cell sub-populations
including regulatory T lymphocytes (Treg) and interleukin (IL)-17 secreting T helper cells (Th17) may
exert antithetical actions in this scenario. Phenotype and frequency of circulating immune cell subsets
were assessed by multi-parametric ﬂow cytometry in 29 clinically stable IPF patients and 17 healthy con-
trols. The interplay between Treg lymphocytes expressing transforming growth factor (TGF)-b and Th17
cells was also investigated. Proportion and absolute number of natural killer (NK) cells were signiﬁcantly
reduced in IPF patients in comparison with controls (p < 0.001). Conversely, the proportion and absolute
number of CD3+CD4+CD25highFoxp-3+ cells were signiﬁcantly increased in IPF patients (p = 0.000). As in
controls, almost the totality of cells (>90%) expressed TGF-b upon stimulation. Interestingly, the fre-
quency of Th17 cells was signiﬁcantly compromised in IPF patients (p = 0.000) leading to an increased
TGF-b/IL-17 ratio (4.2 ± 2.3 vs 0.5 ± 0.3 in controls, p = 0.000). Depletion of NK and Th17 cells along with
a not compromised Treg compartment delineate the existence of an ‘‘immune proﬁle’’ that argue against
the recent hypothesis of IPF as an autoimmune disease. Our ﬁndings along with the imbalance of the
Treg/Th17 axis more closely suggest these immune perturbations to be similar to those observed in can-
cer. Clinical relevance, limitations and perspectives for future research are discussed.
 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a progressive and devas-
tating fatal illness with a mean survival of less than 5–6 years from
the onset of clinically relevant symptoms. Disease incidence is on
the rise with estimates ranging from 6.8 to 16.3 cases per year in
the United States [1]. IPF prognosis in a variable proportion of cases
may be further worsened by lung cancer with prevalence estimates
ranging from 4.8% to 48% in different studies and a cumulative
incidence rate increasing over time [2]. Mechanisms underlying
IPF pathogenesis are elusive and not yet clearly elucidated. IPF is
actually considered as an epithelial/ﬁbroblastic disorder resulting
from an unabated continuation of the repair process in response
to recurrent episodes of epithelial injury [3]. Histologically, the dis-
ease hallmark is represented by the accumulation of ﬁbroblastic
foci composed of proliferating and migrating ﬁbroblasts and of dif-
ferentiated myoﬁbroblasts accounting for the deposition of extra-
cellular matrix and alveolus disruption [4]. In agreement with pre-
vious reports, we have recently shown that oxidative stress may
act as a key player in the pathogenesis of IPF [5]; conversely, the
role of inﬂammation along with the involvement of the immune
response still remains largely controversial.
Emerging novel T cell sub-populations including T regulatory
(Treg) lymphocytes and effector interleukin (IL)-17 secreting T
helper cells (Th17) may exert antithetical actions in this scenario.
Notably, regulatory T lymphocytes include different cell subsets
indispensable for the maintenance of immune homeostasis. As a
1043-4666/$ - see front matter  2014 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.cyto.2013.12.003
q This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-No Derivative Works License, which per-
mits non-commercial use, distribution, and reproduction in any medium, provided
the original author and source are credited.
⇑ Corresponding author. Address: Department of Clinical Medicine and Surgery,
Respiratory Medicine Section, Federico II University, Via L. Bianchi, 5, 80131 Naples,
Italy. Tel.: +39 081 706 2773; fax: +39 081 770 2457.
E-mail address: marialuisa.bocchino@unina.it (M. Bocchino).
Cytokine 66 (2014) 119–126
Contents lists available at ScienceDirect
Cytokine
journal homepage: www.journals .e lsev ier .com/cytokine
Author's personal copy
consequence, any dysregulation of such cells may have a signiﬁ-
cant impact in a wide array of human diseases, including cancer
[6]. Indeed, exuberant Treg function has been shown to play an
important role in cancer-mediated immune-suppression [7]. On
the other side, Th17 cells mainly exert a pro-inﬂammatory role
and actively participate in the pathogenesis of autoimmune dis-
eases, allergy and transplantation rejection [8]. Conversely, Th17
impairment contributes to tumor growth and progression [9,10].
Therefore, the better understanding of these players is of relevant
interest especially in the light of the evolving concepts that suggest
the contribution of both cancer-related mechanisms and of auto-
immune processes in the natural history of IPF [11,12]. To date,
only few data addressing the role of Treg cells in IPF pathogenesis
are actually available, at least in the human model. In this issue,
Kotsianidis et al. have ﬁrstly described a global Treg impairment
in IPF patients that was strongly correlated with disease severity
[13]. In agreement with these observations, Shimizu et al. have fur-
ther shown that interstitial Foxp3-positive lymphocytes were de-
creased in the lung of patients with usual interstitial pneumonia
(UIP), and at a lesser extent in that of patients affected by ﬁbrotic
non-speciﬁc interstitial pneumonia (f-NSIP) [14]. These ﬁndings
were correlated with the severity of ﬁbrosis and were due to an
imbalance of the CXCL12/CXCR4 axis. Conversely, to our knowl-
edge, there are no studies addressing the involvement of Th17 cells
speciﬁcally in the clinical context of IPF.
Aim of the present study was to analyze in a more comprehen-
sive fashion the ex vivo distribution and phenotype of immune cell
subsets, including regulatory T cells, by means of multi-parametric
ﬂow cytometry at the peripheral level in a cohort of patients af-
fected by clinically stable IPF. The dynamic inter-relationship be-
tween Treg lymphocytes and Th17 cells was also investigated by
addressing their functional ability to express two cytokines that
are pivotal in the modulation of the immune response, that are
transforming growth factor (TGF)-b and IL-17, respectively.
2. Materials and Methods
2.1. Study population
Twenty-nine consecutive Italian patients affected by stable IPF
who attended the Respiratory Medicine Division of the Federico
II University at the Monaldi Hospital in Naples, Italy, were enrolled
in the study. Diagnostic preliminaries included clinical history,
physical examination, routine blood tests, lung function testing,
arterial blood gases analysis, high resolution computed tomogra-
phy scan (HRCT) of the thorax and echocardiography. The 6 minute
walk test (6MWT) and ﬁberoptic bronchoscopy were performed in
selected cases. Diagnosis of IPF was made according to the recent
American Thoracic Society/European Respiratory Society consen-
sus statement [15]. Exclusion criteria were acute disease exacerba-
tion (including viral and bacterial infections) and systemic
administration of corticosteroids and/or immune-suppressive
drugs at enrolment or in the previous 60 days. Seventeen age-
and sex-matched healthy volunteers were recruited as control
group. The local Ethics Committee approved the study and all par-
ticipants provided written informed consent. Demographics and
clinical characteristics of the study population are shown in Table 1.
Lung function parameters are reported in Table 2.
2.2. Phenotypic analysis of peripheral immune cell subsets
Fresh whole peripheral blood samples were drawn into 0.2%
EDTA-containing Vacutainer tubes. Four aliquots were incubated
for 30 min at 4 C in the dark with the following cocktails of mono-
clonal antibodies (MAbs) conjugated to different ﬂuorochromes, as
reported: (1) Foxp3-FITC, CD152-PE, CD45RO-PerCP-Cy5.5, CD25-
PE-CY7, CD45RA-APC, CD4-APC-CY7; (2) CD62L-FITC, Foxp3-PE,
CD184-PerCP-Cy5.5, CD25-PE-CY7, CD13-APC, CD4-APC-CY7; (3)
CD158-FITC, CD16-PE, CD161-PerCP-Cy5.5, CD56- PE-CY7, CD8-
APC; and (4) CD4-PE, CD3-PerCP-Cy5.5, CD20-APC, CD8-APC-CY7.
Matched isotype MAbs were used as negative controls. All reagents
were purchased from Becton Dickinson (BD, San Diego, CA, USA).
Intracellular staining for Foxp3-Alexa Fluor 488 (clone 259D/C7)
and Foxp3-PE (clone 259D/C7) was performed according to the
manufacturer’s instructions (BD Bioscences Pharmingen). After
red cell lysis with ammonium chloride (BD FACS Lysing Solution
BD Bioscences Pharmingen), 50.000 total events were acquired
for each sample by means of a 6-color staining FACS Canto II
(BD). Data analysis was performed with the FACS Diva software
(BD). Selection of the lymphocytes containing gate was based on
side/forward scatter. An additional aliquot of blood was used for
white blood cells and lymphocytes counts determination per
mm3 via haemocytometer (XT-1800i Sysmex Europe, Norderstedt,
Germany). Frequency of Foxp-3+ regulatory T lymphocytes was
calculated as percentage of CD3+CD4+CD25high cells. The absolute
number per mm3 of any cell subset was calculated as follows: per-
cent of a given cell subset  total number of lymphocytes per
mm3/100.
2.3. Dynamics of regulatory T lymphocytes and Th17 cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples by centrifugation on a Ficoll-Hypaque gradient (Fi-
coll-Paque™ Plus, GE Healthcare Bio-Scences AB), washed and
resuspended in RPMI 1640 (Lonza, Bioresearch) supplemented
with 10% fetal calf serum (EuroClone Group), 2 mmol/l L-glutamine
(Lonza, Bioresearch), 10 UI/ml penicillin and 10 lg/ml streptomy-
cin (Lonza, Bioresearch). For single-cell analysis of TGF-b and IL-
17 synthesis, respectively by regulatory and Th17 cell subsets,
two different aliquots of 1  106 PBMCs/ml were cultured in 3 ml
of complete medium and stimulated with 10 ng/ml PMA and
1 lg/ml Ionomycin (both purchased from Sigma Aldrich) for
18 hrs at 37 C and 5% CO2. During the last 12 hrs of culture 2 ll/
ml monensin (Golgi Stop, BD) was added in one out of two culture
plates in order to induce the intracellular accumulation of newly
synthesized proteins. The untreated plate was used as positive
control of secretion of targeted cytokines. Two aliquots of 1  106 -
cells/ml of monesin-treated cells were then stained with the fol-
lowing cocktails of monoclonal Abs: (1) Foxp-3-FITC, TGF-b-PE,
CD45RO-PerCP-Cy5.5, CD25-PerCP-CY7, CD45RA-APC, CD8-APC-
CY7; (2) CD4-PE, CD3-PerCP-Cy5.5, CD8-PerCP-CY7, IL-17-APC. A
single aliquot of 1  106/ml monesin-untreated cells was instead
stained with the following monoclonal Abs: Foxp-3-FITC, TGF-b-
PE, CD4-PerCP-Cy5.5, CD25-PerCP-CY7, IL-17-APC, CD8-APC-CY7.
Surface staining was performed as previously described. Intracellu-
lar staining of Foxp-3, TGF-b and IL-17 was performed at 4 C for
30 min in previously saponin/formaldehyde (Cytoﬁx/Cytoperm
buffer purchased from BD) treated samples. Matched isotype MAbs
were used as negative controls. The lymphocytic gate was selected
as previously reported and used to count 30.000 events. Frequency
of TGF-b expressing Foxp-3+ regulatory T lymphocytes was calcu-
lated as percentage of CD8 CD25high cells. Frequency of Th17 cells
was expressed as proportion of CD3+CD4+CD8IL-17+ cells. The
TGF-b/IL-17 ratio was calculated as follows: frequency of TGF-b
expressing Foxp-3+CD8CD25high regulatory T lymphocytes/fre-
quency of CD3+CD4+CD8IL-17+ cells.
2.4. Statistical analysis
All statistical analyses were performed with the SPSS version
16.0 (SPSS, Chicago, IL) and with the statistical platform R version
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2.15 (RDevelopment Core Team, 2102). Continuous variables are re-
ported as mean ± standard deviation (SD) (standard error of the
mean, SEM) and median [25th–75th percentile range]; categorical
variables are reported as number of occurrences and percentages.
For all study variables, comparison among controls and IPF subjects
was based on the non-parametric Wilcoxon–Mann–Whitney exact
test. Spearman correlation coefﬁcient was computed to investigate
the correlations between the different cell subsets. For all analyses,
weused two-sided tests,withp values <0.05 denoting statistical sig-
niﬁcance. However, due to the large number of the variables exam-
ined, in order to control the family-wise error rate at level a = 0.05,
the signiﬁcance of the p values associated to the Mann–Whitney U
statistics and to the Spearman correlation coefﬁcients was further
assessed by using the adaptive Bonferroni procedure [16].
3. Results
3.1. IPF patients display a signiﬁcant depletion of peripheral NK cells
Ex vivo frequency distribution and quantiﬁcation of peripheral
blood immune cell subsets were realized by means of multi-
parametric ﬂow cytometry analysis in 29 clinically stable IPF pa-
tients and in 17 healthy volunteers. Main results are displayed in
Table 3. As shown, no signiﬁcant differences were recorded com-
paring the mean proportions and absolute numbers (data not
shown) of both CD4+ and CD8+ T cells and of their ratio in the
two study groups. Interestingly, in agreement with a previous re-
port by Gilani et al. [17] showing that the co-stimulatory molecule
CD28 was down-regulated on circulating CD4+ T lymphocytes in
poor prognosis IPF patients, the percentage of CD28+CD4+ T cells
was slightly decreased in IPF patients. However, this ﬁnding was
no more relevant after multiple test correction. No differences
were reported when comparing their absolute number in the study
groups (data not shown). As for CD4+ and CD8+ T cells, no differ-
ences in the distribution of CD20+ B lymphocytes were observed
between IPF and control subjects. Conversely, both the proportion
and the total count of NK cells were markedly decreased in IPF pa-
tients as compared to controls. Similarly, a signiﬁcant decrease of
the percentage of NKT cells (but not of their absolute number)
was also found in IPF patients in comparison with the control
group; however, this ﬁnding was no more statistically relevant
after multiple test correction.
Table 1
Demographics and main clinical features of IPF patients.
Parameter IPF patients Controls
Age (years) 64 ± 9.8 (1.9); 65 [59.9–68.1] 62 ± 3.6
Gender 21 M/8 F 12 M/5 F
Smoking history 20 Ex/9 never smokers 10 Smokers/7 never smokers
Pack/years 40.5 ± 35.5 (8.6); 35 [22.2–58.8] 31 ± 11 (3.5); 30 [23.4–39.2]
Risk factors Recurrent respiratory infections (n = 6) –
Occupational exposure (n = 8)
Time of ﬁrst diagnosis 2008 (n = 3), 2009 (n = 5), 2010 (n = 8), 2011 (n = 9), 2012 (n = 4) –
Emphysema n = 6 –
Pulmonary hypertensiona n = 5
Co-morbidities Gastro-esophageal reﬂux (n = 10) –
Ischemic heart disease (n = 6)
Systemic hypertension (n = 8)
Type II diabetes (n = 6)
Other (n = 10)
Previous IPF therapies No (n = 14), Yes (n = 15) –
Corticosteroids (n = 12)
N-acethyl-cysteine (n = 7)
Immune-suppressor agents (n = 2)
Experimental trials (n = 1)
Long term O2 supplementation No (n = 16), Yes (n = 13) –
Data are expressed as means ± SD (SEM); median [IQR25–IQR75].
a sPAP (systolic pulmonary arterial pressure) was estimated by means of echocardiography.
Table 2
Functional characteristics of IPF patients.
Parameter IPF patients Controls
paO2 (mmHg) (21% FiO2 at rest) 69.5 ± 13.6 (2.8); 71.6 [63.8–75.3] –
% SpO2 (21% FiO2 at rest) 92.3 ± 5.7 (1.2); 95 [89.9–94.7] 97 ± 1.4 (0.4); 97 [96–98]a
FVC (L) 3.1 ± 4.0 (0.9); 2.4 [1.3–4.9] 3.4 ± 0.7 (0.3); 3.3 [2.6–4.0]
FVC (% pred) 69.8 ± 18.7 (3.9); 69 [61.5–78.1] 98.4 ± 13 (4.9); 91 [86.2–110]
TLC (L) 3.5 ± 1.3 (0.3); 3.3 [2.7–4.2] 5.0 ± 0.9 (0.3); 4.9 [4.3–5.6]
TLC (% pred) 60.6 ± 18.7 (5); 61 [49.8–71.4] 85.6–38 (1.2); 85.5 [82.8–88.3]
DLCOsb (Hb-adjusted) (ml/min/mmHg) 9.3 ± 4.5 (1.0); 8.7 [7.1–11.5] 23.3 ± 6.1 (2.0); 23.3 [18.5–27.9]
DLCOsb (Hb-adjusted) (% pred) 41.9 ± 17.8 (4.1); 41 [33.2–50.6] 85.1 ± 4.17 (1.3); 84.5 [82.1–88]
DLCO/AV (ml/min/mmHg) 3.1 ± 0.9 (0.2); 3.1 [2.6–3.5] 4.9 ± 0.7 (0.3); 4.9 [4.2–5.4]
DLCO/AV (% pred) 75.2 ± 25.1 (5.8); 81 [63.1–87.3] 109 ± 19.2 (6.8); 114 [93–125]
6 MWT distance (m) 405 ± 139 (35); 390 [331–479] –
Data are expressed as means ± SD (SEM); median [IQR25–IQR75].
Abbreviations: PaO2 = arterial O2 partial pressure; FiO2 = fraction of inspired oxygen; SpO2 = oxygen saturation; FVC = forced vital capacity; DLCOsb = single breath diffusing
lung capacity of carbon monoxide; Hb = haemoglobin; AV = alveolar volume; TLC = total lung capacity; and 6 MWT = six-minute walk test.
a Oxygen saturation was evaluated by means of percutaneous pulse-oxymetry.
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3.2. Frequencies and absolute numbers of regulatory T cells are
increased in IPF
Flow cytometry estimates of frequencies of circulating regula-
tory T lymphocyte subsets are reported in Table IV. As shown,
the mean proportion and absolute number of CD3+CD4+CD25high-
Foxp-3+ cells were signiﬁcantly increased in IPF patients in com-
parison with control subjects, as also conﬁrmed by multiple test
correction. However, no differences were found when looking at
the distribution of naïve (CD45RA+) and effector (CD45RO+) sub-
sets, the majority of cells (>90%) expressing the CD45RO marker
in both study groups. In order to further characterize the distribu-
tion of blood T regulatory cells the expression pattern of three
additional surface molecules, such as CXCR4, CTLA-4 and CD62L,
was investigated. As shown in Table 4, again no substantial differ-
ences were recorded in IPF cases in comparison with control
subjects Fig. 1.
3.3. Impairment of Th17 cells leads to a signiﬁcant imbalance of the
TGF-b/IL-17 axis in IPF
To address the extent of the functional performance of regula-
tory T cells in IPF, measurement of intracellular TGF-b expression
was assessed upon in vitro stimulation as described in Section 2.
Concomitantly, the ability of CD4+ T lymphocytes to produce IL-
17 was also investigated. As shown in Fig. 2A, the mean proportion
of regulatory T cells expressing TGF-b was signiﬁcantly higher in
IPF patients than in controls. Almost the totality of cells was re-
cruited upon stimulation in the two study groups with the involve-
ment of both naïve and effector cells (Fig. 2, panel B). However, the
contribution to TGF-b expression by the latter cell subset was less
impressive in IPF patients (Fig. 2, panel B). Representative counter
plots for TGF-b expression by regulatory T lymphocytes in an
healthy subject and in an IPF patient are respectively shown in
panels C and D of Fig. 2. Interestingly, the mean frequencies of
IL-17 expressing helper T lymphocytes was signiﬁcantly compro-
mised in IPF patients, as illustrated in Fig. 3 (panels A and B). Rep-
resentative counter plots for IL-17 expression by helper T cells in
an healthy subject and in an IPF patient are shown in panels C
and D (Fig. 3). Expression of TGF-b and IL-17 was not detectable
in monesin-untreated cell samples suggesting that both cytokines
were secreted upon synthesis (data not shown). Finally, as re-
ported in Fig. 4, the TGF-b/IL-17 ratio was dramatically increased
in IPF patients in comparison with controls. This ﬁnding was inver-
sely correlated in a signiﬁcant manner with the percentage of Th17
cells (Spearman Rho: 0.81, p < 0.001; signiﬁcant after multiple
test correction).
3.4. Frequencies and dynamics of blood immune cell subsets are not
associated with IPF severity
No correlations were found between the distribution of any cir-
culating immune cell subset studied (either as percentage or abso-
lute number) and IPF associated parameters of disease severity,
previous therapy and smoking history. Similarly, perturbations of
TGF-b and IL-17 expression were not correlated with any dis-
ease-related indicator. Follow-up data are available over a period
of 20 ± 3.8 months. Six patients are died due to rapidly worsening
of respiratory failure, 15 cases have experienced a progressive clin-
ical and functional decline, while the remaining 8 patients still re-
main stable, according to the reference criteria [15]. No
correlations between the immunological parameters analyzed
and the clinical outcome (that is, died, deterioration, or stability)
were found.
Table 3
Distribution of peripheral immune cell subsets in IPF patients.
Parameter CTR (n = 17) IPF (n = 29) pa Signiﬁcance after multiple test correction
WBCs count/ll 7711 ± 1918 (465) 8842 ± 1988 (398) ns No
7500 [6725–8698] 8800 [8021–9663]
% Lymphocytes 33.8 ± 7.1 (1.7) 29.9 ± 7.8 (1.5) ns No
33.1 [30.2–37.5] 29.1 [26.7–33.1]
Number of lymphocytes/ll 2615 ± 900 (218) 2624 ± 937 (187) ns No
2381 [2152–3078] 2430 [2237–3012]
% CD3+CD4+ T lymphocytes 42.8 ± 4.5 (1.1) 38.5 ± 10.7 (2.6) ns No
43 [40.4–45.1] 36.5 [32.9–44]
% CD3+CD8+ T lymphocytes 39.3 ± 7.5 (1.8) 34.9 ± 10.3 (2.5) ns No
32.1 [25.4–33.2] 33.9 [29.6–40.2]
CD4+/CD8+ T cell ratio 1.4 ± 0.5 (0.1) 1 ± 0.6 (0.1) ns No
1.2 [1–1.7] 0.9 [0.7–1.3]
% CD3+CD4+CD28+ lymphocytes 42.5 ± 6.3 (2) 34.5 ± 14.5 (2.9) 0.034 No
41.1 [39.6–47.6] 31.7 [24–44.3]
Number of CD3+CD4+CD28+ lymphocytes/ll 1200 ± 511 (161) 960 ± 610 (125) ns No
1065 [834–1565] 807 [702–1218]
% CD3+CD20+ B lymphocytes 9.4 ± 5.1 (1.2) 9.1 ± 6.5 (1.4) ns No
7.6 [6.7–12] 7.2 [6.1–12]
% CD3CD16+CD56+ natural killer (NK) cells 11.8 ± 4.5 (1.1) 6.9 ± 5.8 (1.3) 0.001 Yes (weak)
11 [7.6–17] 5.7 [3.6–8.6]
Number of CD3CD16+CD56+ NK cells/ll 309 ± 149 (36) 185 ± 197 (40) 0.001 Yes (weak)
298 [189–395] 153 [87–233]
% CD3+CD16+ natural killer T (NKT) cells 7.7 ± 4.1 (1.0) 5.1 ± 5.5 (1.2) 0.009 No
6.4 [4.5–10.7] 3.3 [2–6.1]
Number of CD3CD16+NKT cells/ll 191 ± 98 (24) 138 ± 179 (38) 0.017 No
204 [110–240] 76 [40–181]
ns = Not signiﬁcant.
a See Section 2 for details.
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4. Discussion
Aim of the present study was to investigate the distribution of
peripheral immune cell subsets in patients affected by clinically
stable idiopathic pulmonary ﬁbrosis. Interestingly, we found that
both the percentage and absolute number of NK cells were signif-
icantly reduced in IPF patients. This ﬁnding is in contrast with a
previous report showing that peripheral NK cells were increased
in a small cohort of 11 IPF patients [18]. Result differences may
be explained, at least in part, by the adoption of different criteria
for diagnosing IPF and by the inclusion as control group of patients
affected by other interstitial lung diseases instead of healthy
subjects. The sample size may also have been an issue of concern.
In the present study, we further observed that similar perturba-
tions, although at a lesser extent, were also applicable to NKT cells.
Actually, there are no information addressing dynamics of NK and
NKT cells in IPF pathogenesis for any comparison with our data;
conversely, depletion of these cell subsets has been more exten-
sively investigated in cancer biology [19,20]. Overall, analysis of
CD4+ and CD8+ T cells and of B lymphocytes showed the lack of sig-
niﬁcant differences among IPF and control subjects.
To the best of our knowledge, this is also the ﬁrst research
addressing the distribution of circulating regulatory T lympho-
cytes, Th17 cells, and their balance in IPF patients. Despite these
Table 4
Distribution of peripheral regulatory T cell subsets in IPF patients.
Parameter CTR (n = 17) IPF (n = 29) pa Signiﬁcance after multiple test correction
% CD3+CD4+CD25highFoxP3+ (Treg) cells 0.4 ± 0.2 (0.04) 0.68 ± 0.3 (0.06) 0.000 Yes (strong)
0.4 [0.2–0.5] 0.6 [0.5–0.8]
Number of Treg cells/ll 7.2 ± 4.1 (1.0) 18.0 ± 10.8 (2.1) 0.000 Yes (strong)
5.8 [3.3–10.9] 15.5 [10.7–23.9]
% CD45RA+ T reg cells (naive) 7.0 ± 4.4 (1.0) 4.8 ± 3.3 (0.7) ns No
7.2 [3.9–9.8] 4.3 [2.6–6.6]
% CD45RO+ Treg cells (effectors) 91.7 ± 5.9 (1.4) 91.9 ± 9.6 (1.9) ns No
92.4 [88.7–96.1] 94 [91.2–97]
% CTLA-4+ Treg cells 74.1 ± 10.9 (3.0) 62.8 ± 29.7 (7.0) ns No
72.5 [48–77.6] 72.8 [48–77.6]
% CD62L+ Treg cells 66.8 ± 15.9 (4.4) 66.1 ± 19.3 (4.4) ns No
63.3 [57.2–76.5] 71.1 [56.8–75.4]
% CXCR4+ Treg cells 52.1 ± 27.3 (7.8) 36.3 ± 25.9 (5.4) ns No
63.4 [34.8–69.5] 32.5 [25–47.5]
ns = Not signiﬁcant.
a See Section 2 for details.
Fig. 1. Counter dot plots representing percentages of Treg cells in a control subject (A) and in IPF patient (B). Total lymphocytes (previously selected according to forward and
side scatter parameters and CD3 expression) were gated on CD4 and CD25. CD4+CD25high T cells were then gated on FOX-P3, as Treg cells. Frequencies of CD4+CD25high FOX-
P3 T cells are reported as percentage of total lymphocytes.
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two novel T cell subpopulations share a common origin, they have
a reciprocal relationship as exert mutually antagonistic functions.
To date, the role of Treg cells in the pathogenesis of IPF is a matter
of debate due to controversial results emerging from still limited
evidence, at least in humans. Difﬁculties in this context are further
increased due to the lack of an animal model strictly representative
of human IPF. In this issue, recent data suggest regulatory T cells to
exert differential roles in the animal model of bleomycin-induced
ﬁbrosis along with disease progression. Indeed, as reported by Bov-
eda-Ruiz et al., Treg cells seem to be detrimental in early stages of
lung disease, but protective later on [21]. In agreement with these
ﬁndings, also Trujillo et al. have postulated Treg cells to be beneﬁ-
cial to the host in an attenuated form of bleomycin-related lung
ﬁbrosis induced in CCR7 deﬁcient mice [22]. Similarly, Treg protec-
Fig. 2. Distribution and analytical data of peripheral TGF-beta expressing Treg cells are reported in IPF patients in comparison with control subjects in panels A and B,
respectively. Representative ﬂow cytometry counter plots in a healthy control (panel C) and in a IPF patient (panel D) are also shown. Numbers in the dot plots indicate the
percentages of TGF-beta positive Treg cells.
Fig. 3. Distribution and analytical data of peripheral Th17 cells are reported in IPF patients in comparison with control subjects in panels A and B, respectively. Representative
ﬂow cytometry counter plots in a healthy control (panel C) and in a IPF patient (panel D) are also shown. Numbers in the dot plots indicate the percentages of IL-17 positive
CD3+CD8 T cells.
124 D. Galati et al. / Cytokine 66 (2014) 119–126
Author's personal copy
tion was already been reported in the S.rectivirgula-induced hyper-
sensitivity pneumonitis animal model, by suppressing the produc-
tion of interferon (IFN)-c by CD4+ and CD8+ T cells [23].
We found that both the frequency and absolute number of
blood CD4+CD25highFoxp3+ cells were signiﬁcantly increased in
our cohort of clinically stable IPF cases when compared to normal
subjects. This observation accounted for an increased proportion of
cells expressing TGF-beta in IPF patients. Ability to express TGF-
beta was however comparable to that of control subjects as almost
the entire pool of Treg cells (>90%) was functionally recruited upon
stimulation in both study groups. Distribution of Treg subsets, that
are naïve (CD45RA+) and effector/mature (CD45RO+) cells, was
quite similar in controls and IPF patients and equally contributed
to the expression of TGF-beta. In a similar manner, we found no
substantial differences when looking at the expression of surface
markers of homing (CXCR4 and CD62L) and of suppressive function
(CTLA-4), overall suggesting similar dynamics in cell turn-over and
activation. In disagreement with our data, Kotsianidis et al. have
recently shown that broncho-alveolar lavage (BAL) and peripheral
blood (PB) CD4+CD25+ natural regulatory T cell numbers were re-
duced in IPF patients compared with those of healthy volunteers
and patients without IPF (including patients with connective vas-
cular disease-related interstitial pneumonitis) [13]. However, com-
parisons among study groups were not always statistically
relevant. In addition, they reported that the suppressive potential
of such cells was signiﬁcantly compromised, BAL Treg cell activity
being highly correlated with parameters of disease severity (with
correlation analysis performed only in a small sample of IPF pa-
tients). Similarities in Treg cells impairment and IPF severity have
been reported also by Shimizu et al. [14]. Further similar informa-
tions are available in different additional models of human lung
ﬁbrosis, not necessarily sharing common underlying pathways,
which include granulomatous processes, like berillios and sarcoid-
osis [24–26], and autoimmune disorders with pulmonary involve-
ment [27,28]. Apart from differences in technical procedures, a
main limitation of our study that does not allow any comparison
with literature reports is certainly represented by the lack of data
collected at the BAL level. Overall, in our opinion, there is still not
sufﬁcient information for deﬁnitively allocate Treg cells in the
unresolved puzzle of IPF pathogenesis.
By far, there is no information concerning the role and distribu-
tion of Th17 cells in this issue, whereas these cells have been more
largely studied in autoimmune disorders with lung involvement/
ﬁbrosis, as discussed below. In healthy individuals, approximately
1% of PB CD4+ T lymphocytes is represented by Th17 cells [29].
Interestingly, we found that the frequency of IL-17 expressing
CD4+ helper cells was dramatically reduced in IPF patients in com-
parison with the control group. Conversely, increased frequencies
of Th17 cells along with Th22 lymphocytes (belonging to the
Th17 cell family) have been reported in systemic sclerosis, the lat-
ter being associated as novel biomarker with interstitial lung dis-
ease [30]. Similarly, a skewed distribution of Th17 cells was
suggested in a previous report to be involved in the pathogenesis
of Wegener’s granulomatosis, as they were found to be increased
in patients with active disease but not in those with disease in
remission [31]. Finally, in an animal model of silica-induced ﬁbro-
sis, the contribution to disease progression of Th17 cells was piv-
otal for the induction of early inﬂammation, while it appeared to
be dispensable for the development of the ﬁbrotic response later
on [32]. As a consequence of Th17 depletion, we further observed
that IPF patients exhibited a functional imbalance of the Treg/Th17
axis that resulted to be increased by 8-times. In our opinion, this
ﬁnding is of crucial importance since it is plausible to assume that,
as for the Th1/Th2 dichotomy, any even subtle variation of the
Treg/Th17 interplay may lead to signiﬁcant perturbations of the
immune response thus affecting the natural history of a given dis-
ease. This is also the case in patients affected by different types of
cancer where the increased Treg/Th17 ratio has been recently
shown to be negatively correlated with the disease stages
[33–37]. Conversely, loss of balance between Th17 and regulatory
T lymphocytes toward an increase of the former cells have been
described, for instance, to occur more likely in inﬂammation-
Fig. 4. Distribution and analytical data of the peripheral TGF-beta/IL17 ratio are reported in IPF patients in comparison with control subjects in panels A and B, respectively.
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related diseases like HIV infection [38], and in autoimmune disor-
ders, like myasthenia gravis, Kawasaki disease, and rheumatoid
arthritis [39–41].
5. Conclusions
Altogether, our data argue against the hypothesis that patho-
genesis of IPF, no more considered as an inﬂammatory disorder,
may be driven by an autoimmune process (as suggested by others).
Depletion of NK and Th17 cells along with a not compromised Treg
compartment delineate the existence of an ‘‘immune proﬁle’’ in IPF
that may be more closely assimilated to that observed in the cancer
model. This is not surprising due to the poor prognosis of such a
disease and to the widely recognized unresponsiveness to drugs
with anti-inﬂammatory and/or immuno-suppressive activity. Fur-
ther efforts in larger study populations are requested to address
in a more precise fashion the contribution and dynamics of these
critical players of the immune response in IPF. Their lung distribu-
tion and turn-over also need to be studied, as differences in cell
compartmentalization cannot actually be rule out. This may help
researchers and clinicians to identify predictive markers of disease
phenotypes and outcomes and to improve the tailored develop-
ment of future therapeutic strategies.
Authors contributions
D.G., A.T. and M.N. performed the experiments. M.D.M., G.C.,
A.A.S. and A.S. enrolled the patients. G.R. reviewed all radiological
data. D.B. performed statistical analysis. D.G. and M.B. designed
the study. M.B. enrolled the patients, coordinated the study and
wrote the paper.
References
[1] Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and
prevalence of idiopathic pulmonary ﬁbrosis. Am J Respir Crit Care Med
2006;174:810–6.
[2] Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al.
Cumulative incidence of and predictive factors for lung cancer in IPF.
Respirology 2009;14:723–8. http://dx.doi.org/10.1111/j.1440-1843.2009.
01547.x.
[3] Selman M, Pardo A. Idiopathic pulmonary ﬁbrosis: an epithelial/ﬁbroblastic
cross-talk disorder. Respir Res 2002;3:3.
[4] King Jr TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron Jr JA, et al.
Idiopathic pulmonary ﬁbrosis: relationship between histopathologic features
and mortality. Am J Respir Crit Care Med 2001;164:1025–32.
[5] Bocchino M, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, et al. Reactive
oxygen species are required for maintenance and differentiation of primary
lung ﬁbroblasts in idiopathic pulmonary ﬁbrosis. PLoS One 2010;5:e14003.
[6] Sakaguchi S, Miyara M, Costantino CM, Haﬂer DA. FOXP3+ regulatory T cells in
the human immune system. Nat Rev Immunol 2010;10:490–500.
[7] Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, et al. PGE2 contributes
to TGF-b induced T regulatory cell function in human non-small cell lung
cancer. Am J Transl Res 2010;2:356–67.
[8] Wilke CM, Bishop K, Fox D, ZouW. Deciphering the role of Th17 cells in human
disease. Trends Immunol 2011;32:603–11.
[9] Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. Th17
cells promote cytotoxic T cell activation in tumor immunity. Immunity
2009;31:787–98.
[10] Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to
reduced tumor growth and metastasis. Blood 2009;114:357–9.
[11] Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary ﬁbrosis: a disease
with similarities and links to cancer biology. Eur Respir J 2010;35:496–504.
[12] Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski
JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary ﬁbrosis.
J Immunol 2007;179:2592–9.
[13] Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos
P, et al. CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary ﬁbrosis.
Am J Respir Crit Care Med 2009;179:1121–30.
[14] Shimizu Y, Dobashi K, Endou K, Ono A, Yanagitani N, Utsugi M, et al. Decreased
interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with
discrepancy of CXCL12/CXCR4 axis. Int J Immunopathol Pharmacol 2010;23:
449–61.
[15] Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An ofﬁcial
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary ﬁbrosis: evidence-based
guidelines for diagnosis and management. Am J Respir Crit Care Med
2011;183:788–824.
[16] Guo W. A note on adaptive Bonferroni and Holm procedures under
dependence. Biometrika 2009;96:1012–8.
[17] Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-
regulation on circulating CD4 T cells is associated with poor prognosis of
patients with idiopathic pulmonary ﬁbrosis. PLoS One 2010;5:e8959.
[18] Esposito I, Perna F, Ponticiello A, Perrella M, Gilli M, Sanduzzi A. Natural killer
cells in Bal and peripheral blood of patients with idiopathic pulmonary ﬁbrosis
(IPF). Int J Immunopathol 2005;18:541–5.
[19] Salagianni M, Baxevanis CN, Papamichail M, Perez SA. New insights into the
role of NK cells in cancer immunotherapy. Oncoimmunology 2012;1:205–7.
[20] Pilones KA, Aryankalayil J, Demaria S. Invariant NKT cells as novel targets for
immunotherapy in solid tumors. Clin Dev Immunol 2012;2012:720803. http://
dx.doi.org/10.1155/2012/720803 [Epub 2012 October 17].
[21] Boveda-Ruiz D, D’Alessandro-Gabazza CN, Toda M, Takagi T, Naito M,
Matsushima Y, et al. Differential role of regulatory T cells in early and late
stages of pulmonary ﬁbrosis. Immunobiology 2013;218:245–54.
[22] Trujillo G, Hartigan AJ, Hogaboam CM. T regulatory cells and attenuated
bleomycin-induced ﬁbrosis in lungs of CCR7/ mice. Fibrogenesis Tissue
Repair 2010;3:18. http://dx.doi.org/10.1186/1755-1536-3-1.
[23] Park Y, Oh SJ, Chung DH. CD4+CD25+ regulatory T cells attenuate
hypersensitivity pneumonitis by suppressing IFN-c production by CD4+ and
CD8+ T cells. J Leuk Biol 2009;86:1427–37.
[24] Mack DG, Lanham AM, Falta MT, Palmer BE, Maier LA. Deﬁcient and
dysfunctional regulatory T cells in the lungs of chronic beryllium disease
subjects. Am J Respir Crit Care Med 2010;181:1241–9.
[25] Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The
immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006;203:
359–70.
[26] Idali F, Wahlström J, Müller-Suur C, Eklund A, Grunewald J. Analysis of
regulatory T cells associated forkhead fox P3 expression in the lungs of
patients with sarcoidosis. Clin Exp Immunol 2008;152:127–37.
[27] Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global
natural regulatory T cell depletion in active systemic lupus erythematosus. J
Immunol 2005;175:8392–400.
[28] Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and
migration capacity of CD4+CD25+ regulatory T cells in systemic lupus
erythematosus. Rheumathology 2008;47:789–94.
[29] Wilkie CA, Bishop K, Fox D, ZouW. Deciphering the role of Th17 cells in human
disease. Cell 2011;32:603–11.
[30] Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C. Increased
frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in
systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther
2011;13:R166.
[31] Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed
distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis
in remission. Arthritis Rheum 2008;58:2196–205.
[32] Lo Re S, Dumoutier L, Couillin I, Van Vyve C, Yakoub Y, Uwambayinema F, et al.
IL-17A-producing cdT and Th17 lymphocytes mediate lung inﬂammation but
not ﬁbrosis in experimental silicosis. J Immunol 2010;184:6367–77.
[33] Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, De Marzo AM, et al.
Phenotypic analysis of prostate-inﬁltrating lymphocytes reveals TH17 and
Treg skewing. Clin Cancer Res 2008;14:3254–61.
[34] Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH, et al. Involvement of T helper type
17 and regulatory T cell activity in tumour immunology of bladder carcinoma.
Clin Exp Immunol 2010;161:480–9.
[35] Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, et al.
Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-inﬁltrating
lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes
in patients with gastric cancer. Cancer Sci 2010;101:1947–54.
[36] Wang J, Cai D, Ma B, Wu G, Wu J. Skewing the balance of regulatory T-cells and
T-helper 17 cells in breast cancer patients. J Int Med Res 2011;39:691–701.
[37] Zhao L, Yan J, Wang HP, Liu RY. Imbalance in the Th17/Treg and cytokine
environment in peripheral blood of patients with adenocarcinoma and
squamous cell carcinoma. Med Oncol 2013;30:461. http://dx.doi.org/
10.1007/s12032-013-0461-7 [Epub 2013 January 20].
[38] Di L, Chen J, Jia M, Hong K, Ruan Y, Liang H, et al. Loss of balance between T
helper type 17 and regulatory T cells in chronic human immunodeﬁciency
virus infection. Clin Exp Immunol 2011;165:363–71.
[39] Masuda M, Matsumoto M, Tanaka S, Nakajima K, Yamada N, Ido N, et al.
Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells
in myasthenia gravis patients. J Neuroimmunol 2010;225:123–31.
[40] Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell
imbalance in patients with acute Kawasaki disease. Clin Exp Immunol
2010;162:131–7.
[41] Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S. The Th17/Treg imbalance and
cytokine environmental in peripheral blood of patients with rheumatoid
arthritis. Rheumatol Int 2012;32:887–93. http://dx.doi.org/10.1007/s00296-
010-1710-0 [Epub 2011 January 11].
126 D. Galati et al. / Cytokine 66 (2014) 119–126
